A rumor regarding Arcutis Biotherapeutics (ARQT) was highlighted in an alert sent to subscribers of Ben Harrington’s takeover-focused Betaville blog, contacts tell The Fly. Shares of the biotech company are up 54c, or 5%, to $11.95 in afternoon trading.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics price target raised to $20 from $18 at Needham
- Arcutis Biotherapeutics reports preliminary Q4 revenue $63M, consensus $54.95M
- Arcutis Biotherapeutics price target raised to $20 from $19 at Mizuho
- American Air upgraded, Nordstrom downgraded: Wall Street’s top analyst calls
- Arcutis Biotherapeutics initiated with a Buy at H.C. Wainwright